SCHOTT Pharma and SHL Medical Advance Integrated Solutions for Large-Volume Drug Delivery

SCHOTT Pharma and SHL Medical Advance Integrated Solutions for Large-Volume Drug Delivery

(IN BRIEF) SCHOTT Pharma has pre-validated its SCHOTT TOPPAC® ISO-standardized polymer cartridge for compatibility with SHL Medical’s Maggie® large-volume autoinjector platform. The collaboration delivers a ready-to-use, de-risked solution for administering highly sensitive biologics in large volumes, supporting self-injection and home-care therapies. With further compatibility studies underway, the partnership continues to expand integrated drug delivery options for pharmaceutical companies.

(PRESS RELEASE) MAINZ, 15-Jan-2026 — /EuropaWire/ — SCHOTT Pharma has reached a new milestone in its collaboration with SHL Medical by pre-validating the SCHOTT TOPPAC® polymer cartridge for compatibility with SHL Medical’s Maggie® large-volume autoinjector platform. The achievement marks the first time a sterile polymer cartridge platform has been verified for use with the Maggie® autoinjector system, offering pharmaceutical companies a pre-validated solution for large-volume drug delivery.

The SCHOTT TOPPAC® cartridge is the first polymer cartridge in SCHOTT Pharma’s portfolio to comply with ISO dimensions while also meeting the global ready-to-use standard, SCHOTT iQ®. Designed to address the demanding requirements of modern therapeutics, the polymer cartridge is well suited for highly sensitive biologics, including cell and gene therapies, biosimilars and emergency medications. Polymer materials are particularly beneficial in applications requiring reduced silicone exposure or storage at very low temperatures.

Compatibility studies jointly conducted by SCHOTT Pharma and SHL Medical evaluated both the dimensional accuracy and functional performance of the SCHOTT TOPPAC® polymer cartridges when integrated with the Maggie® autoinjector platform. The assessment confirmed full system compatibility, covering the 3 ml SCHOTT TOPPAC® cartridge with the Maggie® 3.0 ml autoinjector and the 5 ml cartridge with the Maggie® 5.0 ml version. This pre-validation enables pharmaceutical companies to access a de-risked, integrated solution for the safe and convenient administration of large-volume therapies, supporting self-injection in home-care settings.

As part of the SCHOTT iQ® platform, the polymer cartridges are supplied in a standard nest-and-tub configuration, simplifying fill-and-finish operations and helping manufacturers shorten development timelines and accelerate market entry. Alongside the polymer option, SCHOTT Pharma’s 3 ml and 5 ml cartriQ® glass cartridges have also been confirmed as compatible with the Maggie® autoinjector systems, giving drug developers flexibility in material selection based on the specific needs of each therapy and patient population.

Building on this progress, SCHOTT Pharma and SHL Medical are continuing their collaboration with further studies planned to assess compatibility between the SCHOTT TOPPAC® polymer cartridge and SHL Medical’s pen injector platforms. Additional evaluations with other medical devices are also underway, expanding the potential for integrated drug delivery solutions across a broader range of applications.

The pre-validated system will be presented at Pharmapack Paris on January 21–22, where SCHOTT Pharma will showcase the polymer cartridge and its compatibility with SHL Medical’s large-volume autoinjectors.

About SCHOTT Pharma

Human health matters. That is why SCHOTT Pharma designs containment solutions grounded in science to ensure that medications are safe and easy to use for people around the world. Every minute, more than 30,000 people receive an injection packed in a SCHOTT Pharma product. The portfolio comprises drug containment solutions and delivery systems for injectable drugs ranging from prefillable glass and polymer syringes to cartridges, vials, and ampoules. Every day, a team of around 4,800 people from over 65 nations works at SCHOTT Pharma to contribute to global health. The company is represented in all main pharmaceutical hubs with 17 manufacturing sites in Europe, North and South America, and Asia. With over 1,000 patents and technologies developed in-house and a state-of-the-art R&D center in Switzerland, the company is focused on developing innovations for the future. Currently, SCHOTT Pharma has over 1,800 customers including the top 30 leading pharma manufacturers for injectable drugs and generated revenue of EUR 986 million in the fiscal year 2025. SCHOTT Pharma AG & Co. KGaA is headquartered in Mainz, Germany and listed on the Frankfurt Stock Exchange as part of the SDAX. It is majority owned by SCHOTT AG, which is owned by the Carl Zeiss Foundation. In light of this spirit, SCHOTT Pharma is committed to sustainable development for society and the environment. Further information at www.schott-pharma.com

Media Contact:

Lea Kaiser
PR & Communications Manager
+49 (0) 6131 66-2422

SOURCE: SCHOTT Pharma